Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma - Related Studies

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

This study is currently recruiting participants.

Study NCT00561418. Last updated on October 8, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma
		Small Intestine Cancer

2	Additional conditions recognized in this trial
		Duodenal Neoplasms
		Ileal Neoplasms
		Intestinal Neoplasms
		Jejunal Neoplasms

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Duodenal Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Ileal Diseases
		Immune System Diseases
		Immunoproliferative Disorders
		Intestinal Diseases
		Jejunal Diseases
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site

4	Interventions listed in this trial
		vorinostat
		DNA analysis
		immunologic technique
		laboratory biomarker analysis

5	Additional drug interventions recognized in this trial
		Suberoylanilide hydroxamic acid

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Anticarcinogenic Agents
		Antineoplastic Agents
		Antirheumatic Agents
		Central Nervous System Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protective Agents
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Arthur G. James Cancer Hospital &Richard J. Solove Research Institute
		National Cancer Institute (NCI)